Artelo Biosciences, Inc. Warrant
ARTLW
ARTLW was delisted on the 17th of June, 2024.
4 hedge funds and large institutions have $8K invested in Artelo Biosciences, Inc. Warrant in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
11% less capital invested
Capital invested by funds: $9K → $8K (-$1K)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14 |
Top Sellers
ARTLW Hedge Fund Activity: Q1 2022 in Review
4 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences, Inc. Warrant (ARTLW) for Q1 2022, worth a combined $8K — down 11% from $9K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARTLW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $14.
- 4 institutional investors held Artelo Biosciences, Inc. Warrant (ARTLW) as of Q1 2022, down from 5 in Q4 2021.
- Funds reported $8K of Artelo Biosciences, Inc. Warrant stock for Q1 2022, down 11% quarter-over-quarter.
- 0 funds opened new Artelo Biosciences, Inc. Warrant positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest Artelo Biosciences, Inc. Warrant buyer in Q1 2022 was UBS Group, an estimated $14 added.
Based on aggregated 13F filings for Q1 2022.